Get started
Author

Cecile Raymond

Observed name: Cécile Raymond
ORCID: 0009-0009-6622-1969
Observed ORCID: 0009-0009-6622-1969
OpenAlex ID: A5115778845
NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2025 · Sara Majocchi, Pauline Lloveras, et al. · Cancer Immunology Research · 12
PDF
Figure S13 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S03 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S14 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S05 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S17 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S12 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S16 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S10 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S11 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S03 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S15 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S02 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S08 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S05 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S02 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S09 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Works count: 52
Citation count: 12
H-index: 1
I10-index: 1
Year
Topic
Type